Merck KGaA and GlaxoSmithKline are ending a partnership for the oncology asset bintrafusp alfa which could have netted billions for the German pharma if successful.
But the data just didn’t pan out that way in multiple tests, most recently a phase 2 clinical trial in locally advanced or metastatic biliary tract cancer that was discontinued due to futility.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,